There are advantages to conducting cardiovascular magnetic resonance (CMR) studies at a field strength of 3.0 Telsa, including the increase in bulk magnetization, the increase in frequency separation of off-resonance spins, and the increase in T1 of many tissues. However, there are significant challenges to routinely performing CMR at 3.0T, including the reduction in main magnetic field homogeneity, the increase in RF power deposition, and the increase in susceptibility-based artifacts.In this review, we outline the underlying physical effects that occur when imaging at higher fields, examine the practical results these effects have on the CMR applications, and examine methods used to compensate for these effects. Specifically, we will review cine imaging, MR coronary angiography, myocardial perfusion imaging, late gadolinium enhancement, and vascular wall imaging.

Level of Evidence: 5 Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2019.

Purpose To provide an overview of the types of adverse events reported to the US Food and Drug Administration (US FDA) for magnetic resonance (MR) systems over a 10‐yr period. Methods Two reviewers independently reviewed adverse events reported to FDA for MR systems from 1 January 2008 to 31 December 2017 and manually categorized events into eight event types. Thermal events were further subcategorized by probable cause. Objects that became projectiles were also categorized. Results FDA received 1568 adverse event reports for MR systems between 1 January 2008 and 31 December 2017. This analysis included 1548 reports. Thermal events were the most commonly reported serious injury (59% of analyzed reports). Mechanical events — defined as slips, falls, crush injuries, broken bones, and cuts; musculoskeletal injuries from lifting or movement of the device — (11%), projectile events (9%), and acoustic events (6%) were also observed. Conclusions Adverse events related to MR systems consistent with the known hazards of the MR environment continue to be reported to FDA. Increased awareness of the types of adverse events occurring for MR imaging systems is important for prevention.

The study protocol was HIPAA compliant and institutional review board approved. Informed consent was obtained from all participants. The purpose of the study was to prospectively validate the capability of navigator-echo-gated phase-contrast magnetic resonance (MR) imaging for measurement of myocardial velocities in a phantom and to prospectively use the phase-contrast MR sequence to measure three-directional velocity in the myocardium in vivo in volunteers and in patients scheduled for cardiac resynchronization therapy. An excellent correlation between the measured velocity and the true phantom motion (R = 0.90 for longitudinal velocity, R = 0.93 for circumferential velocity) was observed. Myocardial velocities were successfully measured in 17 healthy volunteers (11 male, six female; mean age, 27.5 years +/- 6.5 [standard deviation]) and 28 patients with heart failure (18 male, 10 female; mean age, 63.9 years +/- 15.0). Velocity values were significantly lower in the patients than in the volunteers. The time to peak velocity in the lateral wall of the patients, as compared with that in the volunteers, was delayed. Phase-contrast MR imaging can be combined with navigator-echo gating to measure three-directional myocardial tissue velocities in vivo.